MX2024013843A - Compuestos dirigidos a bmr y métodos de uso asociados - Google Patents

Compuestos dirigidos a bmr y métodos de uso asociados

Info

Publication number
MX2024013843A
MX2024013843A MX2024013843A MX2024013843A MX2024013843A MX 2024013843 A MX2024013843 A MX 2024013843A MX 2024013843 A MX2024013843 A MX 2024013843A MX 2024013843 A MX2024013843 A MX 2024013843A MX 2024013843 A MX2024013843 A MX 2024013843A
Authority
MX
Mexico
Prior art keywords
pyrazino
cancer
treatment
hexahydro
pyridazine derivatives
Prior art date
Application number
MX2024013843A
Other languages
English (en)
Spanish (es)
Inventor
John A Rose
Corey Howard Basch
Song Mei
Klare Lazor Bersh
Danielle Julie Beam Roth
Katarina Rohlfing
Xiaowei Wu
Artem Shvartsbart
Andrew Paul Combs
Liang Lu
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2024013843A publication Critical patent/MX2024013843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2024013843A 2022-05-10 2024-11-08 Compuestos dirigidos a bmr y métodos de uso asociados MX2024013843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340185P 2022-05-10 2022-05-10
PCT/US2023/066755 WO2023220577A1 (en) 2022-05-10 2023-05-09 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024013843A true MX2024013843A (es) 2025-02-10

Family

ID=86771366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013843A MX2024013843A (es) 2022-05-10 2024-11-08 Compuestos dirigidos a bmr y métodos de uso asociados

Country Status (10)

Country Link
US (1) US20230365576A1 (enExample)
EP (1) EP4522621A1 (enExample)
JP (1) JP2025521091A (enExample)
KR (1) KR20250011136A (enExample)
CN (1) CN119487036A (enExample)
AU (1) AU2023269778A1 (enExample)
CA (1) CA3252552A1 (enExample)
IL (1) IL316891A (enExample)
MX (1) MX2024013843A (enExample)
WO (1) WO2023220577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026090411A1 (en) 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119504710B (zh) * 2024-11-18 2025-10-17 昆明医科大学 靶向降解PRMT5的PROTACs化合物及其应用
CN121873038A (zh) * 2026-03-16 2026-04-17 南开大学 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Also Published As

Publication number Publication date
KR20250011136A (ko) 2025-01-21
JP2025521091A (ja) 2025-07-08
WO2023220577A1 (en) 2023-11-16
IL316891A (en) 2025-01-01
CA3252552A1 (en) 2023-11-16
CN119487036A (zh) 2025-02-18
AU2023269778A1 (en) 2024-12-12
US20230365576A1 (en) 2023-11-16
EP4522621A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
PH12022550754A1 (en) Pyrido[3,2-d]pyrimidine compounds as immunomodulators
MX2025013504A (es) Inhibidores de kras de anillo fundido para el tratamiento de enfermedades
AU2019231551A8 (en) Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
MX2022011601A (es) Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer.
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
MX2022009534A (es) Inhibidores de ectonucleotido pirofosfatasa/fosfofiesterasa 1 (enpp1) y metodos de uso de los mismos.
MXPA02011426A (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa.
TW200510380A (en) Mitotic kinesin inhibitors
ATE432923T1 (de) 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
MX2025010149A (es) [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4
YU84603A (sh) Novi inhibitori tirozin kinaze
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
IL158667A0 (en) Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AU2002342878A1 (en) Pyridylpyrimidine derivatives as effective compounds against prion diseases
WO2021074620A9 (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
MA34844B1 (fr) Derives de (1,2,4) triazolo[4,3-a]quinoxaline comme inhibiteurs de phosphodiestérases
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2025002794A (es) Compuestos citotoxicos de imidazo[1,2-a]piridina y su uso en terapia
ATE242246T1 (de) (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
TWI264437B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
WO2022058745A3 (en) Imidazo[1,2-a]pyridine compounds and their use in therapy
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)
WO2024163641A3 (en) Formulations for treating cancer